Studies in our lab have shown that inflammatory signals are key drivers of cardiac fibrosis and the use of pharmacologic antagonists e. Current studies are also aimed at factors that govern the pattern of fibrosis in specific forms of heart failure HF. For example, the nature of fibrosis around small blood vessels appears to differ according to the stage and severity of HF. Recent data also suggest that perivascular fibrosis may also be present in other tissue of the body in HF and this may be very important in patients with HF.
Aging Dis. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther. Mescher AL. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Cell Signal. Leask A. Circ Res. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. Investigational drugs targeting cardiac fibrosis.
Expert Rev Cardiovasc Ther. Heart disease. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Stem cell transplantation as a therapy for cardiac fibrosis. J Pathol. ACE2, angiotensin- and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol.
Hypertension vaccine may be a boon to millions in developing world. Hum Vaccin Immunother. FDA approves Esbriet to treat idiopathic pulmonary fibrosis.
Accessed October 27, Kissei Pharmaceutical Co. Kissei entered into an agreement with Nuon Therapeutics, Inc on Tranilast. Accessed October 22, Tracleer bosentan product information. Letairis ambrisentan product information.
Hashimura, H. Radiologic-pathologic correlation of primary and secondary cardiomyopathies: MR imaging and histopathologic findings in hearts from autopsy and transplantation. Heusch, G. Cardiovascular remodelling in coronary artery disease and heart failure.
Lancet , — Heymans, S. Heart Fail. Ho, C. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Imaging 6, — Ho, J. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
Hofmann, U. Horn, M. Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. Hulsmans, M. Monocyte and macrophage contributions to cardiac remodeling. Jordana, M. Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax 43, — Karamitsos, T. The role of cardiovascular magnetic resonance imaging in heart failure. Kato, S. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction.
Kim, J. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
Kockova, R. Native T1 relaxation time and extracellular volume fraction as accurate markers of diffuse myocardial fibrosis in heart valve disease- comparison with targeted left ventricular myocardial biopsy. Komada, T. Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement.
Nagoya J. Kong, P. The pathogenesis of cardiac fibrosis. Life Sci. Kuwahara, F. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Kvakan, H. Regulatory T cells ameliorate angiotensin II-induced cardiac damage.
Lagan, J. Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases. Leary, P. Histamine H2 receptor antagonists, left ventricular morphology, and heart failure risk: the MESA study. Leong, D. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography.
Levick, S. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53, — Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Liu, T. Late gadolinium enhancement amount as an independent risk factor for the incidence of adverse cardiovascular events in patients with stage C or D heart failure. Lopez, B. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.
Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. Lopez-Andres, N. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF Cardiac Resynchronization in Heart Failure trial.
Loring, Z. Noninvasive Electrocardiol. Mishra, P. Cardiac matrix: a clue for future therapy. Acta , — Mollmann, H. Bone marrow-derived cells contribute to infarct remodelling. Montgomery, R. Therapeutic inhibition of miRa improves cardiac function and survival during heart failure.
Moore-Morris, T. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. Moravsky, G. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc. Munch, J.
Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy.
Murray, P. Protective and pathogenic functions of macrophage subsets. Nevers, T. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Oyamada, S. Panizo, A. Are mast cells involved in hypertensive heart disease? Passino, C. Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Acta , 29— Ponikowski, P. Prockop, D. Collagens: molecular biology, diseases, and potentials for therapy.
Raina, S. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. Imaging 9, — Roncarati, R. Circulating miRa, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
Rudolph, A. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. Ruparelia, N. Inflammatory processes in cardiovascular disease: a route to targeted therapies.
Russo, A. Samuel, C. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension 64, — Satoh, H. Distribution of late gadolinium enhancement in various types of cardiomyopathies: significance in differential diagnosis, clinical features and prognosis.
World J. Schroer, A. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease. Cell Sci. Segura, A. Fibrosis and heart failure. Spinale, F. Membrane-associated matrix proteolysis and heart failure. Sun, Y. Angiotensin, I. Cell Cardiol. Tang, T. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res. Taylor, A. T1 mapping: basic techniques and clinical applications.
Imaging 9, 67— Thum, T. Noncoding RNAs and myocardial fibrosis. Nature , — Tietjens, J. Serelaxin and acute heart failure. Heart , 95— Upadhya, B. Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. Imaging 43, — MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Drug Discov. Control of stress-dependent cardiac growth and gene expression by a microRNA.
Science , — Villar, A. Myocardial and circulating levels of microRNA reflect left ventricular fibrosis in aortic stenosis patients. Watanabe, K. Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis.
Allergy Drug Targets 10, — Weber, K. Patterns of myocardial fibrosis. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Wei, L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Wynn, T. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Yancy, C. Ypenburg, C. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Yu, Q. T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice.
Matrix Biol. Zacharski, D. Xyloglucan from Tropaeolum majus Seeds induces cellular differentiation of human keratinocytes by inhibition of egfr phosphorylation and decreased activity of transcription factor CREB.
Biomacromolecules 16, — Zeisberg, E. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Zhao, X. Keywords: mycardial fibrosis, heart failure, late gadolinium enhancement, micro RNAs miRNAs , biomarkers, extracelluar matrix. The use, distribution or reproduction in other forums is permitted, provided the original author s or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these terms.
0コメント